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ABSTRACT
Objective: The identification of a vitamin D–responsive (VDRE) motif within the HLA-DRB1*15:01
promoter region provides an attractive explanation for the combined effects of HLA-DR inheri-
tance and vitamin D exposure on multiple sclerosis (MS) risk. We therefore sought to incorporate
HLA-DRB1 promoter variation, including the VDRE motif, in an assessment of HLA-DRB1–
associated MS risk.
Methods: We utilized 32 homozygous HLA cell lines (covering 17 DRB1 alleles) and 53 heterozy-
gote MS samples (20 DRB1 alleles) for HLA-DRB1 promoter sequencing. The influence of HLA-
DRB1 variation on MS risk was then assessed among 466 MS cases and 498 controls.
Results: The majority of HLA*DRB1 alleles (including HLA-DRB1*15:01) express the functional
VDRE motif, apart from HLA-DRB1*04, *07, and *09 alleles that comprise the HLA-DR53 sero-
logic group. Allele-specific variation within functional X-box and Y-box motifs was also associated
with serologically defined HLA-DR haplotypes. Incorporating these results in an analysis of
MS risk, we identified a strong protective effect of HLA-DRB1*04, *07, and *09 (DR53) alleles
(p  10
12) and elevated risk associated with DRB1*15 and *16 (DR51) and *08 (DR8) alleles
(p  10
18).
Conclusions: HLA-DRB1 groups corresponding to serologic HLA-DR profiles as well as promoter
polymorphism haplotypes effectively stratified MS risk over an 11-fold range, suggesting func-
tional relationships between risk-modifying HLA-DRB1 alleles. An independent contribution of
VDRE motif variation to increase MS risk was not discernible, although vitamin D–dependent
regulation of HLA-DR expression may still play an important role given that HLA-DRB1*04/*07/
*09 (DR53) alleles that express the “nonresponsive” VDRE motif were associated with signifi-
cantly reduced risk of MS. Neurology
® 2012;79:538–546
GLOSSARY
ABMDR  Australian Bone Marrow Donor Registry; AH  ancestral haplotype; HARP  heterozygous ambiguity resolving
primer; MS  multiple sclerosis; OR  odds ratio; PDDD  Perth Demyelinating Disease Database; VDR  vitamin D receptor;
VDRE  vitamin D–responsive element.
The strong effect of geographic location on multiple sclerosis (MS) risk, described in 19211 and
refined in studies incorporating meteorologic data,2,3 reflects a protective influence of sunlight
exposure that is most evident in early life,4 and may even be relevant to in utero development.5,6
These benefits are mediated at least in part via vitamin D, derived naturally from sunlight
exposure or through supplementation.7 Irrespective of the source, activated vitamin D exerts a
range of immune-modulating functions8,9 via vitamin D receptors (VDR) and their target
nuclear vitamin D response elements (VDREs).10
In this context, recent data11 have suggested a direct link between vitamin D and the domi-
nant genetic risk factor HLA-DRB1*15:01, present in more than 50% of MS cases.12 This
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HLA-DRB1*15:01 promoter region that en-
hances gene expression in response to vitamin
D stimulus11 (also observed for HLA-DRB1*
03:01 in an unrelated study13), while other
HLA-DRB1 alleles studied were found to
carry an alternative promoter sequence that is
nonresponsive to vitamin D. These authors11
provided a cogent argument that for HLA-
DRB1*15 bearing individuals, a lack of vita-
min D during early life could allow
autoreactive T cells to escape thymic dele-
tion,11 providing a plausible common path-
way for the effects of sunlight exposure and
HLA-DRB1*15:01 carriage on MS suscepti-
bility. We have sought to further delineate
this effect through a comprehensive analysis
of HLA-DRB1 promoter sequence variation
and allelic diversity in relation to MS disease
risk.
METHODS Research participants. A total of 466 Cauca-
sian participants in the Perth Demyelinating Disease Database
(PDDD) with a diagnosis of clinically definite or probable MS
according to the Poser criteria14 or of MS using the McDonald
criteria15 were included in the study. Of these, 425 (91.2%) were
classified as relapsing-remitting MS. The study population
included 354 female cases (76%), of whom 94% had relapsing-
remitting MS, and 112 male cases (81% with relapsing-
remitting MS). Patients were assessed by the same 2 neurologists
(A.G.K. and W.M.C.) at the time of collecting blood samples.
The control group consisted of 498 healthy Caucasian individu-
als (288 [58%] female) from the Australian Bone Marrow Donor
Registry (ABMDR). With regard to participation in other stud-
ies of genetic susceptibility to MS, 1 case only from these 466
cases was included in the International MS Genetic Consortium,
and 90 cases were included in the ANZGene study cohort. No
control subjects were involved in these studies.
Standard protocol approvals, registrations, and patient
consents. The study protocol was approved by the Sir Charles
Gairdner Hospital Human Research Ethics Committee, and in-
formed consent was obtained from all participants in the PDDD
cohort. Approval for use of control samples was provided by the
ABMDR ethics committee.
B-cell lines. To ascertain DRB1 promoter sequences we uti-
lized DNA extracted from cell lines with known ancestral haplo-
types (AH). Thirty-two cell lines were selected to obtain
sequence data for 17 DRB1 alleles; some represented more than
once in these cell lines (AH 8.1, 7.1, 52.1, 58.1, 37.1, 46.1,
44.2, and 57.1). In addition, 53 samples from the PDDD cohort
were selected based on HLA-DRB1 alleles present—including 8
homozygous and 42 heterozygous HLA-DRB1*15:01-positive
samples—in order to obtain sequence data for 20 DRB1 alleles.
HLA-DRB1 typing. High-resolution 4-digit HLA-DRB1
genotyping was performed in the Department of Clinical Immu-
nology, PathWest, Royal Perth Hospital by DNA sequencing for
both MS cases and control samples, using a previously reported
method.16 Automated sequencing was carried out on the ABI
Prism 3730 and 3730xl Genetic Analyzers and HLA-DRB1
analysis was carried out using ASSIGN V4.0.1.36 (Conexio
Genomics). All HLA typing results for MS samples were resolved
to the 4-digit level using heterozygous ambiguity resolving prim-
ers (HARPs) where applicable. For control samples, sequence-
based typing methods provided 2-digit resolution and NMDP
codes of possible heterozygous HLA-DRB1 combinations (see
reference 17 for further information).
HLA-DRB1 promoter genotyping. HLA-DRB1 promoter
genotyping was also performed in the Department of Clinical
Immunology PathWest, Royal Perth Hospital, using the follow-
ing methods. DNA was extracted from whole blood using the
QIAGEN BioRobot M48 machine using QIAGEN Magattract
DNA Blood Mini M48 kit. The PCR was performed in a 30 L
volume, consisting of 2 L genomic DNA (at approximately 50
ng/L), 10  PCR buffer (15 mM MgCl2, 100 mM Tris-HCl
pH 8.4, 500 mM KCl, 1 mg/mL of gelatin, 0.2% of NP-40), 1
mM of each dNTP (Life Technologies, Rockville, MD), and 2.5
units of Taq Platinum polymerase (Life Technologies). The for-
ward primer sequences 5CAATTAAAGTTTTACATG and
5CAATTAAAGTGTTTTACACG were tagged with the uni-
versal M13F sequence, and the reverse primer 5TGTC-
CCCAGMCAAAGCCAGT was tagged with the universal
M13R sequence. Concentrations of all primers were initially
tested at 20 pmol and adjustments to individual primer concen-
trations were made if an allele was suboptimally amplified.
The DNA were amplified following initial denaturation at
96°C for 6 minutes followed by 35 cycles of 96°C for 30 sec-
onds, 70°C for 30 seconds, and 72°C for 2 minutes. A final
extension step was performed at 72°C for 10 minutes. PCR am-
plification was confirmed following electrophoresis using 1% SE
Agarose gel and the PCR amplicons were purified using MIO-
BIO
® PCR purification system. Automated sequencing was per-
formed using ABI Big Dye Terminator chemistry, as per
manufacturer’s instructions, using universal M13F and M13R
sequencing primers as well as group-specific sequencing primers
(5TCTGACCAGCGACTGAT and 5TGTCAGAACTGC-
CATGCA) when required. Samples were purified using the
Agencourt
® CleanSEQ
® PCR purification system prior to se-
quencing on ABI Prism 3730 and 3730xl Genetic Analyzers.
Finally, the HLA-DRB1 promoter analysis was carried out using
ASSIGN ATF 1.0.2.45 (Conexio Genomics).
Statistical analysis. Comparisons of carriage frequencies of
alleles between cases and controls were carried out by Fisher
exact tests for individual alleles or case-control logistic regres-
sions for multivariable analyses. p Values of  0.05 were consid-
ered statistically significant. Analyses were carried out using the
TIBCO Spotfire S statistical package (TIBCO Software Inc.,
Palo Alto, CA). For analyses of HLA-DR associations with MS
risk, 2-digit resolution HLA results were utilized in order to
maximize data availability among controls.
RESULTS HLA-DRB1 allele-specific VDRE sequence
variation. We first sought to examine sequence variation
in the HLA-DRB1 promoter region, including the pre-
viously identified VDRE motif. As shown in figure 1
and table 1, we confirmed the association between
HLA-DRB1*15:01andtheVDREmotif
211GGGTG-
GAGGGGTTCA
225 associated with vitamin D–re-
sponsive HLA-DRB1 gene expression. This VDRE
Neurology 79 August 7, 2012 539sequencewasalsofoundinallHLA-DRB1allelesexam-
ined other than HLA-DRB1*04, *07, and *09 alleles
where an alternative GGGTGGAGAGGGGT-CA se-
quence was identified (differences italicized) that intro-
duced an internal GA insertion between positions 216
and 217 of the DRB1*15:01 reference sequence shown
in figure 1, which is likely to disrupt VDR binding by
shifting the adenine from position 7 where it is invari-
ably located within functional VDRE motifs.10 The re-
sulting loss of VDRE function is consistent with
previous findings that the “alternative” (HLA-
DRB1*04/07/09-associated) VDRE is not responsive
to vitamin D stimulation.11 Among the 85 samples in
which promoter sequencing was undertaken, all con-
formed to the expected patterns of allele-specific pro-
moter polymorphism identified in table 1, including 53
DRB1*15:01-positive samples (3 homozygous cell lines
and 50 MS cohort samples: 8 homozygous and 42
heterozygous at the DRB1 locus).
HLA-DRB1 promoter sequence variation. Investigat-
ing the promoter region more generally (table 1), we
identified sequence identity throughout the entire
promoter region between HLA-DRB1*15:01 and
the closely related DRB1*15:02 and DRB1*16:01
alleles that make up the DR51 haplotype group,18
as well as HLA-DRB1*01 alleles (4 DRB1*01:01,
1 DRB1*01:02, and 3 DRB1*01:03-positive sam-
ples) that share a distant ancestral history with
HLA-DRB1*15:0119 but which display only lim-
ited sequence similarity and epitope binding
preferences.20,21 It is also notable that the HLA-
DRB1*15:01, DRB1*15:02, and DRB1*16:01 al-
leles within the HLA-DR51 haplotype group share
an association with HLA-DRB5, while loss of this
additional HLA-DRB locus has been identified as a
feature of the evolutionary divergence of HLA-
DRB1*01 from the ancestral HLA-DR51 group.19
All 53 HLA-DRB1*15:01-positive samples showed
sequence identity across the promoter region (figure 1).
Looking beyond the VDRE motif region, we
identified HLA allele-associated polymorphism
within regulatory X-box and Y-box motifs (see figure
1) that have been previously shown to influence
constitutive and cytokine-stimulated HLA-DR ex-
pression, respectively.18,22 With regard to the MS-
associated HLA-DRB1*15:01 allele, its X-box
sequence has been associated with high constitutive
gene expression, 4- to 5-fold higher than observed
with DR53-associated HLA-DRB1*04, *07, and *09
alleles, in which the canonical motif is disrupted by
the A-to-G transition at position 106 (figure 1 and
table 1).22 Similarly, polymorphic residues at posi-
tions 139 (G) within the Y-box domain and 164 (C)
within the CCAAT domain of HLA-DRB1*15:01
have been associated with 2-fold increase in DRB1
expression in response to cytokine stimuli (e.g.,
interferon- and tumor necrosis factor-18), while
the HLA-DR53-associated sequence (139C, 164T)
was again associated with nonresponsiveness.18
Taken together, these findings provide evidence
for shared promoter sequence variation within the
HLA-DR51 group (DRB1*15:01, 15:02, 16:01) and
HLA-DRB*01:01, characterized functionally by
high constitutive as well as inducible gene expression
in response to vitamin D/VDR as well as cytokine-
mediated stimuli. This functional VDRE motif is
also shared by HLA-DRB1 alleles within the HLA-
DR52 group (table 1) as well as DRB1*10:01 and
DRB1*08, although these alleles lack the cytokine
responsiveness conferred by the DR51-specific Y-box
and CCAAT motifs. In contrast, the HLA-DR53
group of alleles (DRB1*04, *07, and *09) share pro-
moter polymorphisms that confer both lower consti-
tutive gene expression as well as nonresponsiveness to
both vitamin D– and cytokine-mediated stimuli.
HLA-DRB1 alleles and VDRE variants as MS risk
factors. Having established associations between pro-
moter sequence variation and HLA-DRB1 alleles, we
sought to investigate the potential relevance of these
observations to genetic risk of MS among Caucasian
MS cases (n  466) and controls (n  498). Table 2
describes the rates of HLA DRB1 allele carriage and
homozygosity frequencies among cases and controls,
with odds ratios (ORs) for HLA allele carriage
among MS cases and controls represented in figure 2.
As expected, HLA-DRB1*15 was overrepresented
among cases (n  256, 54.9%) compared with con-
trols (n  135, 27.1%), providing an OR of 3.27
(p  0.001). The closely related HLA-DRB1*16 al-
lele, although low in prevalence (17 cases, 3.6%; 8
Figure 1 Sequence variation in the HLA-DRB1 promoter region
HLA-DRB1 5UTR reference sequence (HLA-DRB1*15:01) showing variation sites (red)
identified by sequence-based typing (see table 1), relative to known regulatory motifs
(in blue, as defined in reference 17) and vitamin D–responsive element motif (in green,
reference 11).
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Neurology 79 August 7, 2012 541controls, 1.6%), was also associated with increased
MS risk (OR 2.32, p  0.066), particularly among
HLA-DRB1*15-negative individuals (OR 3.62, p 
0.005). Similarly, carriage of HLA-DRB1*08 was as-
sociated with MS risk in the overall dataset (29 cases,
6.2%; 16 controls, 3.2%: OR 2.00, p  0.032) with
a more pronounced effect after exclusion of HLA-
DRB1*15 (OR 2.90, p  0.006). No other HLA-
DRB1 alleles were associated with increased MS risk,
either within a restricted dataset of relapsing-
remitting disease (table e-1 and figure e-1 on the
Neurology
® Web site at www.neurology.org) or in
the presence or absence of HLA-DRB1*15 (figure
e-2A and e-2B).
Reduced MS risk was associated with carriage of
the prevalent alleles HLA-DRB1*04 (113 cases,
24.2%; 186 controls, 37.3%: OR 0.54, p  0.0001)
and HLA-DRB1*07 (84 cases, 18.0%; 157 controls,
31.5%:OR0.48, p0.0001).Atrendtowardreduced
risk was also found for the low-prevalence HLA-
DRB1*09 allele (5 cases, 1.1%; 13 controls, 2.6%: OR
0.40, p  0.096). Notably, HLA-DRB1*04 remained
protective among HLA-DRB1*15 heterozygous indi-
viduals (OR 0.55, p  0.023), while the protective
effect of HLA-DRB1*07 was observed in the HLA-
DRB1*15-negative group (OR 0.42, p  0.0001),
but not among HLA-DRB1*15 carriers (OR 1.48,
p  0.29).
Overall, the effects of HLA-DRB1 allele carriage
on MS risk show consistent correlations with the
original HLA-DR serologic groups defined prior to
the availability of sequence-based HLA typing tech-
Table 2 HLA allele carriage (phenotype) and
homozygosity frequency in cases
and controls
Allele carriage Homozygosity
Cases
(466)
Controls
(498)
Cases
(466)
Controls
(498)
No. % No. % No. % No. %
DRB1*01 83 17.8 106 21.3 1 0.2 5 1.0
DRB1*03 110 23.6 122 24.5 15 3.2 10 2.0
DRB1*04 113 24.2 186 37.3 5 1.1 22 4.4
DRB1*07 84 18.0 157 31.5 5 1.1 6 1.2
DRB1*08 29 6.2 16 3.2 0 0.0 1 0.2
DRB1*09 5 1.1 13 2.6 0 0.0 0 0.0
DRB1*10 7 1.5 10 2.0 0 0.0 0 0.0
DRB1*11 53 11.4 55 11 1 0.2 1 0.2
DRB1*12 12 2.6 15 3.0 1 0.2 1 0.2
DRB1*13 75 16.1 85 17.1 4 0.9 6 1.2
DRB1*14 17 3.6 22 4.4 0 0.0 0 0.0
DRB1*15 256 54.9 135 27.1 39 8.4 14 2.8
DRB1*16 17 3.6 8 1.6 0 0.0 0 0.0
Figure 2 Relative risk of multiple sclerosis according to HLA carriage: Odds ratios and 95%
confidence intervals
HLA serologic groups are indicated by color and defined in the left-hand column. Alleles that share promoter sequence
identity with HLA-DRB1*15:01 are indicated with bold italics.
542 Neurology 79 August 7, 2012niques (figure 2), which reflect both the peptide-
binding preferences of these HLA-DRB1 allele
groups19–21 as well as their haplotypic associations
with additional HLA-DRB loci (i.e., HLA-DRB5
[DR51], DRB3 [DR52], and DRB4 [DR53]). Thus,
HLA-DRB1 alleles from the DR53 group appear to
be protective, while those from the DR51 and DR8
group are associated with excess risk. The remaining
DR52 and DR1-associated HLA-DRB1 alleles did
not significantly influence MS risk in this popula-
tion, and it is notable in particular that carriage of
HLA-DRB1*01 was not associated with increased
MS risk in the overall group (OR 0.80, p  0.19) or
in the absence of HLA-DRB1*15 (OR 0.95, p 
0.84) despite sharing complete promoter sequence
identity with HLA-DRB1*15 and DRB1*16 alleles.
Thus, there was no evidence that promoter sequence
variation—either within the VDRE motif or across
the promoter region more generally—acted as a
dominant independent risk factor for MS in this
study.
Considering these findings in terms of the inheri-
tance of serologic HLA-DR profiles, there was a clear
linear effect of HLA-DR53 allele copy number (p
value for trend  1.9  10
12) as well as HLA-
DR51/DR8 allele copy number (p  10
18). Utiliz-
ing these data to stratify genetic risk (figure 3), the
overall effect of these compound genotypes appears
to be consistent with a dominant influence of “high
risk” HLA-DR51 and HLA-DR8 alleles (present in
61.8% of cases and 30.9% of controls), and a reces-
sive protective effect of HLA-DR53 alleles (21.0% of
cases and 49.4% of controls), although independent
allele dosage models cannot be excluded.
DISCUSSION The identification of a vitamin D re-
sponse element in the promoter region of the HLA-
DRB1 gene,11 and the role of allele-specific sequence
variation within this VDRE motif in determining re-
sponsiveness to vitamin D stimulus,11,13 has provided
an attractive mechanism by which the 2 dominant
risk factors for MS—HLA-DRB1 allele carriage and
low environmental vitamin D exposure—may be di-
rectly linked. In this study we have further explored
the role of promoter polymorphism in relation to
HLA-DRB1 alleles represented in Caucasian popula-
tions, demonstrating that the HLA-DRB1*15:01-
associated VDRE motif is widely represented among
Caucasian HLA-DRB1 alleles with the exception of
HLA-DRB1*04, DRB1*07, and DRB1*09 alleles.
Figure 3 Combined effects of HLA-DR profiles on multiple sclerosis risk
Stratification of multiple sclerosis risk according to combined HLA allele profiles, including prevalence rates in cases (n 
466) and controls (n  498): odds ratios and 95% confidence intervals.
Neurology 79 August 7, 2012 543Furthermore, we identified promoter sequence varia-
tion at other regulatory sites within the DRB1 pro-
moter region that have been previously shown to
influence both constitutive and cytokine-stimulated
expression levels.18,22 In this regard, the MS risk-
associated HLA-DRB1*15:01 allele is characterized
by relatively high constitutive expression as well as
responsiveness to both vitamin D/VDR as well as
cytokine stimulation, combined traits that are shared
by several DRB1 alleles that show sequence identity
throughout the promoter region (DRB1*15:02, 16:01,
and 01:01). Conversely, those DRB1 alleles that lack a
vitamin D–responsive VDRE motif (DRB1*04,
DRB1*07, and DRB1*09) are also characterized
by promoter sequence variation within X-box and
Y-box domains that confer low constitutive gene
expression and nonresponsiveness to cytokine stimuli.18,22
In light of these observations, it is interesting that
risk of MS in a large case-control study involving
Caucasian participants from Western Australia could
be effectively stratified according to groups of HLA-
DRB1 alleles that reflect these promoter haplotypes
in part, but which are also defined by their evolution-
ary ancestry,19,21 antigen-binding preferences,20 and
linkage disequilibrium with additional HLA-DRB
loci (i.e., HLA-DRB3/4/5).23 In this respect it is also
notable that the serologic HLA-DR groups originally
defined before the advent of high-resolution
sequence-based typing methods appear to provide a
very useful classification system for assessing MS risk
in this study. Thus, the HLA-DR53 group of alleles
(DRB1*04, DRB1*07, and DRB1*09, each in link-
age disequilibrium with HLA-DRB4) demonstrated
a consistent association with reduced MS risk, while
increased MS risk was associated with the HLA-
DR51 group (DRB1*15:01, DRB1*16:01, associ-
ated with HLA-DRB5 carriage) as well as DR8
(DRB1*08, which has no additional HLA-DRB loci
within the extended HLA-DR haplotype). Both pro-
tective and risk effects were dependent on allele dose
and were highly significant, contributing to a genetic
profile for this study population that could effec-
tively stratify low- and high-risk groups, providing an
11-fold range in disease susceptibility across the
study population (ORs 0.28–3.06, figure 3). These
results need to be interpreted in light of the limita-
tions of the study, both in terms of the influence of
sample size on statistical power as well as the use of
low-resolution (2-digit) DRB1 typing results in this
analysis, so that we were unable to assess any differ-
ential effects of closely related alleles (e.g.,
DRB1*15:01 vs 15:02) on MS risk. Nevertheless, it
is interesting that similar results were obtained from
an analysis of HLA-DR serologic profiles in a Finn-
ish study.24
With regard to the potential influence of VDRE
polymorphism on MS risk, we can conclude that the
trait of vitamin D–responsive HLA-DRB1 gene ex-
pression is not specific to the high-risk DRB1*15:01
allele, and indeed that the functional VDRE motif is
common among a broad range of Caucasian HLA-
DRB1 genotypes, including DRB1 alleles that have
no discernible influence on MS risk. This finding,
however, does not exclude the possibility that early-
life vitamin D exposure may interact with HLA-
DRB1 inheritance as a risk factor for the disease, or
indeed that interactions between the HLA-DRB1
promoter region and environmental- or infection-
derived stimuli such as vitamin D and inflammatory
cytokines may play an important role in modulating
disease risk through epigenetic mechanisms.25 We
did not assess sunlight exposure as a potential vari-
able in the analysis of MS risk in this cohort, but
anticipate that such a study would be more usefully
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544 Neurology 79 August 7, 2012undertaken in a more geographically diverse popula-
tion given that study participants were largely de-
rived from metropolitan Perth, which is located at a
latitude (32°) where early-life UV exposure is likely
to be sufficient to protect against excess MS risk.2,3
These findings suggest that the functional rela-
tionships between HLA-DR alleles, both in terms of
their promoter sequence characteristics18,22 as well as
their peptide-binding characteristics,19–21,26 can be
usefully explored to identify HLA-DRB1 allele-
specific and shared genetic traits that contribute to
MS risk. We therefore submit that the results of this
study provide a platform for further analyses in larger
study populations with sufficient statistical power to
comprehensively examine the influence of HLA-
DRB1 promoter sequence variation, allele distribu-
tion, and serologic profiles on MS risk. In this regard,
the collaborative efforts of the International Multiple
Sclerosis Genetic Consortium have now provided an
unprecedented opportunity to conduct such analyses
based on existing data,27 with the additional benefit
of a broad geographic distribution that also allows for
the incorporation of environmental sunlight expo-
sure as an additional variable. It is our hope that fur-
ther exploration of these important genetic risk
factors will contribute toward an improved under-
standing of the role of HLA-restricted adaptive im-
munity in MS susceptibility.
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